Bryan has an extensive 20+ year career in healthcare and biotech innovation. In 2020, he co-founded Vanquish Bio with Jacki Kornbluth to leverage groundbreaking research in natural killer derived extra cellular vesicles. He previously spun-out Lung Therapeutics (LTI) from the University of Texas, served on the LTI’s initial board, and recruited its first CEO (LTI was later acquired by Aileron Therapeutics). He formed Cernostics out of the Geisinger Health System and the University of Pittsburgh to market precision pathology software (Cernostics was acquired by Castle Biosciences). He was a member of the founding team at Agentase to commercialize immobilized enzyme platform technology (Agentase was acquired by Flir/ICX). He has significant experience in health and biomedical partnering. He served in a leadership role at AdventHealth, and was the chief business officer of the Early Stage Clinical Research Unit (CRU). In this role, he led financing, partnering and operations for 200 cancer trials. , including Phase 1, 2, 3, and 4 (outcomes) studies. Bryan founded the UT Horizon Fund, raising $60 million in new funding. Mr. Allinson focuses on strategy, leadership and growth.